Search

Your search keyword '"Igarashi, Hisaka"' showing total 126 results
Start Over Author "Igarashi, Hisaka"
126 results on '"Igarashi, Hisaka"'

7. Underrecognition of migraine‐related stigmatizing attitudes and social burden: Results of the OVERCOME Japan study.

Author

Igarashi, Hisaka, Komori, Mika, Ueda, Kaname, Zagar, Anthony J., Jaffe, Dena H., Matsumori, Yasuhiko, Takeshima, Takao, and Hirata, Koichi

Subjects
*SOCIAL attitudes, *MIGRAINE, *SOCIAL stigma, *INTERNET surveys, *HEADACHE
Abstract

Introduction: Migraine‐related stigma (MiRS) and social burden is increasingly recognized. We assessed perspectives and attitudes toward migraine in people with and without migraine in Japan. Methods: OVERCOME (Japan) was a cross‐sectional, population‐based web survey of people with and without migraine (July−September 2020). People with migraine were individuals who met the modified International Classification of Headache Disorders criteria or had self‐reported physician‐diagnosed migraine. People without migraine were selected per quota sampling to represent the Japanese adult population. People with migraine reported their experiences on stigma and social burden and answered how frequently they experienced stigma using the MiRS questionnaire. Associations between MiRS and disability and MiRS and interictal burden were examined using the migraine disability assessment and Migraine Interictal Burden Scale‐4. People without migraine reported their experiences and attitudes toward people with migraine by answering an 11‐item attitudinal migraine questionnaire. Results: A total of 17,071 and 2008 people with and without migraine, respectively, completed the survey. Overall, 11,228 (65.8%) respondents with migraine reported that they have never experienced stigma or burden; however, of the 12,383 employed respondents, 5841 (47.2%) reported that their current employers are not "extremely" or "very" understanding about their conditions. Moreover, ∼30%−40% of respondents "sometimes," "often," or "very often" hid their migraine from others. The proportion of respondents who experienced stigma often or very often, as assessed by MiRS, was 16.5%; this increased with the increasing number of monthly migraine headache days. The proportion of respondents with moderate‐to‐severe disability and interictal burden increased with increasing stigma. Among respondents without migraine, the proportion holding a stigmatizing attitude toward those with migraine was low (<15%); ∼80% had never experienced work‐ or family‐related stigma or burden. Conclusion: MiRS and burden exist but may be hidden and underrecognized in Japan. Disease awareness and education may be important to prevent and reduce stigma and burden. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Diagnosis, knowledge, perception, and productivity impact of headache education and clinical evaluation program in the workplace at an information technology company of more than 70,000 employees

Author

Sakai, Fumihiko, primary, Igarashi, Hisaka, additional, Yokoyama, Masako, additional, Begasse de Dhaem, Olivia, additional, Kato, Hirohisa, additional, Azuma, Yasuhiro, additional, Koh, Rachel, additional, Phillips, Heather, additional, Singh, Nim, additional, Craven, Audrey, additional, Dodick, David W, additional, and Miyake, Hitoshi, additional

Published
2023
Full Text
View/download PDF

10. A multicenter, open-label, phase 3 study to evaluate the safety of fremanezumab for migraine, subcutaneously self-administered with an auto-injection device at institutional sites and at home

Author

Hirata, Koichi, primary, Takeshima, Takao, additional, Imai, Noboru, additional, Igarashi, Hisaka, additional, Shiosakai, Masako, additional, Inage, Masanobu, additional, Sakurai, Fumi, additional, Ning, Xiaoping, additional, Nakai, Masami, additional, and Koga, Nobuyuki, additional

Published
2022
Full Text
View/download PDF

16. Additional file 3 of A study to investigate the prevalence of headache disorders and migraine among people registered in a health insurance association in Japan

Author

Sakai, Fumihiko, Hirata, Koichi, Igarashi, Hisaka, Takeshima, Takao, Nakayama, Takeo, Sano, Hiromi, Kondo, Hiroyuki, Shibasaki, Yoshiyuki, and Koga, Nobuyuki

Abstract

Additional file 3. Sex and age distribution of each headache type and the prevalence of headache type after weighting by age and sex

Published
2022
Full Text
View/download PDF

18. sj-pdf-1-cep-10.1177_03331024221118929 - Supplemental material for Efficacy of lasmiditan for the acute treatment of perimenstrual migraine

Author

MacGregor, E Anne, Komori, Mika, Krege, John Henry, Baygani, Simin, Vincent, Maurice, Pavlovic, Jelena, and Igarashi, Hisaka

Subjects
FOS: Psychology, FOS: Clinical medicine, 170199 Psychology not elsewhere classified, 110319 Psychiatry (incl. Psychotherapy), 110306 Endocrinology, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 110904 Neurology and Neuromuscular Diseases, Neuroscience
Abstract

Supplemental material, sj-pdf-1-cep-10.1177_03331024221118929 for Efficacy of lasmiditan for the acute treatment of perimenstrual migraine by E Anne MacGregor, Mika Komori, John Henry Krege, Simin Baygani, Maurice Vincent, Jelena Pavlovic and Hisaka Igarashi in Cephalalgia

Published
2022
Full Text
View/download PDF

20. sj-pdf-2-cep-10.1177_03331024221118929 - Supplemental material for Efficacy of lasmiditan for the acute treatment of perimenstrual migraine

Author

MacGregor, E Anne, Komori, Mika, Krege, John Henry, Baygani, Simin, Vincent, Maurice, Pavlovic, Jelena, and Igarashi, Hisaka

Subjects
FOS: Psychology, FOS: Clinical medicine, 170199 Psychology not elsewhere classified, 110319 Psychiatry (incl. Psychotherapy), 110306 Endocrinology, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 110904 Neurology and Neuromuscular Diseases, Neuroscience
Abstract

Supplemental material, sj-pdf-2-cep-10.1177_03331024221118929 for Efficacy of lasmiditan for the acute treatment of perimenstrual migraine by E Anne MacGregor, Mika Komori, John Henry Krege, Simin Baygani, Maurice Vincent, Jelena Pavlovic and Hisaka Igarashi in Cephalalgia

Published
2022
Full Text
View/download PDF

22. A multicenter, open-label, phase 3 study to evaluate the safety of fremanezumab for migraine, subcutaneously self-administered with an auto-injection device at institutional sites and at home

Author

Hirata, Koichi, Takeshima, Takao, Imai, Noboru, Igarashi, Hisaka, Shiosakai, Masako, Inage, Masanobu, Sakurai, Fumi, Ning, Xiaoping, Nakai, Masami, and Koga, Nobuyuki

Abstract

ABSTRACTBackgroundFremanezumab is a humanized monoclonal antibody against calcitonin gene-related peptide for subcutaneous use to suppress migraine attacks. A phase 3 study was conducted to investigate the safety of autoinjector (AI)-assisted self-injection of fremanezumab 225 mg.Research Design and MethodsThe multicenter, open-label study involving 71 patients with migraine was conducted between June 2020 and November 2020 at ten institutions in Japan. The study consisted of a 4-week (28-day) screening period and an 8-week (57-day) treatment period. According to the investigator’s instructions, all patients successfully performed self-injection for 4 weeks at the institutional site and at home and maintained eDiaries of their headaches. The primary endpoint was safety of the drug based on treatment-emergent adverse events (TEAEs).ResultsTreatment-emergent adverse events were more frequent after at-home injection than after at-site injection, but they were mainly injection site reactions and mostly mild. The safety profile was comparable, raising no concerns compared with what has been reported in previous studies. Both migraine days and headache days were decreased considerably.ConclusionsOverall, AI-assisted, at-home self-injection of fremanezumab was found to be generally safe and well-tolerated. This injection strategy is considered clinically meaningful in view of improved utility of and adherence to the drug.

Published
2023
Full Text
View/download PDF

23. Additional file 1 of Impact of the COVID-19 pandemic on migraine in Japan: a multicentre cross-sectional study

Author

Suzuki, Keisuke, Takeshima, Takao, Igarashi, Hisaka, Imai, Noboru, Danno, Daisuke, Yamamoto, Toshimasa, Nagata, Eiichiro, Haruyama, Yasuo, Mitsufuji, Takashi, Suzuki, Shiho, Ito, Yasuo, Shibata, Mamoru, Kowa, Hisanori, Kikui, Shoji, Shiina, Tomohiko, Okamura, Madoka, Tatsumoto, Muneto, and Hirata, Koichi

Abstract

Additional file 1: Table S1. Questionnaire. Table S2. Acute and preventive treatments for headaches in patients with migraine. Table S3. Comparisons between patients with and without new-onset headaches after the COVID-19 pandemic. Table S4. Logistic regression analysis results of new-onset headache (n=603)

Published
2021
Full Text
View/download PDF

24. Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial in Japanese and Korean patients

Author

Sakai, Fumihiko, primary, Suzuki, Norihiro, additional, Kim, Byung‐Kun, additional, Igarashi, Hisaka, additional, Hirata, Koichi, additional, Takeshima, Takao, additional, Ning, Xiaoping, additional, Shima, Tomoko, additional, Ishida, Miki, additional, Iba, Katsuhiro, additional, Kondo, Hiroyuki, additional, and Koga, Nobuyuki, additional

Published
2021
Full Text
View/download PDF

25. Early Onset and Maintenance Effect of Galcanezumab in Japanese Patients with Episodic Migraine

Author

Igarashi,Hisaka, Shibata,Mamoru, Ozeki,Akichika, Day,Kathleen Ann, Matsumura,Taka, Igarashi,Hisaka, Shibata,Mamoru, Ozeki,Akichika, Day,Kathleen Ann, and Matsumura,Taka

Abstract

Hisaka Igarashi,1 Mamoru Shibata,2 Akichika Ozeki,3 Kathleen Ann Day,4 Taka Matsumura3 1Department of Internal Medicine, Fujitsu Clinic, Kawasaki, Japan; 2Department of Neurology, Tokyo Dental College Ichikawa General Hospital, Ichikawa, Japan; 3Eli Lilly Japan K.K., Kobe, Japan; 4Eli Lilly and Company, Indianapolis, IN, USACorrespondence: Taka MatsumuraMedical Science, Medicines Development Unit Japan, Eli Lilly Japan K.K., 4-15-1 Akasaka, Akasaka Garden City 13F, Minato-ku, Tokyo, 107-0052, JapanTel +81 3 5574 9169Fax +81 3 5574 9979Email matsumura_taka@lilly.comPurpose: This study aimed to extensively evaluate the onset and maintenance effect of galcanezumab compared with placebo for the prevention of episodic migraine in Japanese patients.Patients and Methods: This was a post-hoc analysis of a Phase 2, multicenter, randomized, double-blind, placebo-controlled study conducted between December 2016 and January 2019 (ClinicalTrials.gov: NCT02959177). Patients aged between 18 and 65 years with episodic migraine were randomized to receive a monthly injection of galcanezumab (120 mg: N = 115, 240 mg: N = 114) or placebo (N = 230) for 6 months. Outcome measures included onset of effect at weekly and daily intervals—assessed by change from baseline in the number of migraine headache days and the proportion of patients with migraine headache—with galcanezumab versus placebo. To further confirm the onset and maintenance effect, the 50% response rate was also evaluated.Results: The mean change from baseline in weekly migraine headache days was significantly reduced with galcanezumab (– 0.97 days) compared with placebo (– 0.10 days) at week 1 (p ≤ 0.0001), which was maintained at all subsequent weeks up to week 4 (all p ≤ 0.0001 vs placebo). A significantly smaller proportion of galcanezumab-treated patients had migraine headache compared with placebo-treated patients at day 1 after the first injection (13.6% vs 31.4%, r

Published
2021

29. Cerebrovascular Sympathetic Nervous Activity During Cluster Headaches

Author

Igarashi, Hisaka, Sakai, Fumihiko, Suzuki, Syuichi, and Tazaki, Yoshiaki

Subjects
Biomedical and Clinical Sciences, Biological Psychology, Clinical Sciences, Neurosciences, Psychology, Neurology & Neurosurgery, Clinical sciences, Biological psychology
Published
1987

30. Cerebral blood flow and cerebral hematocrit in patients with cerebral ischemia measured by single‐photon emission computed tomography

Author

Sakai, Fumihiko, Igarashi, Hisaka, Suzuki, Syuichi, and Tazaki, Yoshiaki

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Stroke, Brain Disorders, Neurosciences, Adult, Blood Viscosity, Cerebrovascular Circulation, Hematocrit, Humans, Ischemic Attack, Transient, Middle Aged, Tomography, Emission-Computed, Neurology & Neurosurgery
Published
1989

31. Clinical practice guideline for chronic headache 2013

Author

Araki, Nobuo, primary, Takeshima, Takao, additional, Ando, Naoki, additional, Iizuka, Takahiro, additional, Igarashi, Hisaka, additional, Ikeda, Yukio, additional, Ito, Yasuo, additional, Inagaki, Mieko, additional, Imamura, Keiko, additional, Ohkuma, Hirohisa, additional, Ogawa, Karin, additional, Kato, Yuji, additional, Kikui, Shoji, additional, Kitamura, Takayuki, additional, Kudo, Masako, additional, Kuwabara, Kentaro, additional, Gono, Yukari, additional, Kowa, Hisanori, additional, Saigoh, Kazumasa, additional, Sato, Shinya, additional, Shibata, Koichi, additional, Shibata, Mamoru, additional, Shimazu, Tomokazu, additional, Shimizu, Toshihiko, additional, Suzuki, Michiyasu, additional, Takahashi, Yuji, additional, Takekawa, Hidehiro, additional, Doi, Hikaru, additional, Nagata, Eiichiro, additional, Nakano, Toshiya, additional, Hashizume, Masahiro, additional, Hashimoto, Shiori, additional, Hamada, Junichi, additional, Hirata, Koichi, additional, Fujiki, Naoto, additional, Fujita, Mitsue, additional, Yamane, Kiyomi, additional, Wajima, Koichi, additional, and Watanabe, Yuka, additional

Published
2019
Full Text
View/download PDF

37. Efficacy of acupuncture on VDT workers(2)

Author

KIKUCHI, Tomokazu, primary, YAMAGUCHI, Satoru, additional, IGARASHI, Hisaka, additional, OMATA, Hiroshi, additional, SUZUKI, Mari, additional, TANAKA, kouichi, additional, ISOBE, Hideyuki, additional, and MIMURA, Toshihide, additional

Published
2011
Full Text
View/download PDF

41. Efficacy of acupuncture on VDT workers (1)

Author

Mari, Suzuki, primary, Yamaguchi, Satoru, additional, Igarashi, Hisaka, additional, Omata, Hiroshi, additional, Kikuchi, Tomokazu, additional, Tanaka, Koichi, additional, Isobe, Hideyuki, additional, Oono, Shuji, additional, Mimura, Toshihide, additional, and Kimijima, Mariko, additional

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results